MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-19-2026
electroCore Cost of Revenue 2011-2026 | ECOR
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue electroCore
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.24 M | 3.78 M | 2.8 M | 1.62 M | 1.38 M | 1.74 M | 1.16 M | 579 K | 519 K | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.24 M | 519 K | 1.98 M |
Quarterly Cost of Revenue electroCore
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.22 M | 939 K | 1.01 M | - | 1.06 M | 838 K | 888 K | - | 661 K | 585 K | 458 K | - | 258 K | 358 K | 360 K | - | 355 K | 374 K | 364 K | - | 348 K | 273 K | 298 K | - | 354 K | 254 K | 158 K | - | 97.1 K | 240 K | 48.9 K | - | 128 K | 38.7 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.22 M | 38.7 K | 461 K |
Cost of Revenue of other stocks in the Medical instruments industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
107 K | - | - | $ 810 M |  USA |
 |
Becton, Dickinson and Company
BDX
|
11.9 B | $ 154.51 | -1.17 % | $ 44.4 B | USA |
 |
Repligen Corporation
RGEN
|
354 M | $ 117.78 | -0.46 % | $ 6.56 M | USA |
 |
Ekso Bionics Holdings
EKSO
|
5.95 M | $ 9.4 | -11.74 % | $ 22.8 M | USA |
 |
Haemonetics Corporation
HAE
|
612 M | $ 56.83 | 1.05 % | $ 2.86 B | USA |
 |
ICU Medical
ICUI
|
1.41 B | $ 123.31 | -1.53 % | $ 3.04 B | USA |
 |
Intuitive Surgical
ISRG
|
3.42 B | $ 452.07 | -2.67 % | $ 161 B | USA |
 |
Harvard Bioscience
HBIO
|
36.6 M | $ 5.2 | 2.16 % | $ 231 M | USA |
 |
Isoray
ISR
|
3.13 M | - | 0.03 % | $ 108 M | USA |
 |
AngioDynamics
ANGO
|
135 M | $ 10.31 | -13.65 % | $ 421 M | USA |
 |
Repro Med Systems
KRMD
|
15.5 M | $ 4.32 | 1.17 % | $ 200 M | USA |
 |
AtriCure
ATRC
|
134 M | $ 29.07 | 2.68 % | $ 1.39 B | USA |
 |
Pulse Biosciences
PLSE
|
539 K | $ 23.0 | -0.13 % | $ 1.55 B | USA |
 |
InfuSystem Holdings
INFU
|
47.3 M | $ 9.29 | -0.11 % | $ 192 M | USA |
 |
Masimo Corporation
MASI
|
1.09 B | $ 178.59 | 0.33 % | $ 9.52 B | USA |
 |
iRhythm Technologies
IRTC
|
220 M | $ 116.8 | -1.2 % | $ 3.74 B | USA |
 |
Merit Medical Systems
MMSI
|
778 M | $ 67.7 | -0.78 % | $ 4 B | USA |
 |
BioLife Solutions
BLFS
|
8.76 M | $ 19.51 | 1.14 % | $ 899 M | USA |
 |
STERIS plc
STE
|
3.06 B | $ 218.71 | -0.56 % | $ 21.6 B | USA |
 |
Teleflex Incorporated
TFX
|
872 M | $ 117.81 | -0.52 % | $ 5.26 B | USA |
 |
Utah Medical Products
UTMD
|
16.5 M | $ 63.12 | 0.4 % | $ 205 M | USA |
 |
OraSure Technologies
OSUR
|
66.8 M | $ 3.08 | 0.98 % | $ 226 M | USA |
 |
West Pharmaceutical Services
WST
|
1.97 B | $ 254.8 | 0.82 % | $ 18.4 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
1.84 B | $ 11.63 | -0.26 % | $ 2.32 B | USA |
 |
Glaukos Corporation
GKOS
|
75.6 M | $ 112.77 | 0.12 % | $ 5.46 B | USA |
 |
ResMed
RMD
|
1.55 B | $ 224.09 | 0.56 % | $ 32.7 B | USA |
 |
Predictive Oncology
POAI
|
72.6 K | - | - | $ 31.1 M | USA |
 |
Baxter International
BAX
|
7.86 B | $ 16.68 | -0.6 % | $ 8.56 B | USA |
 |
NeuroMetrix
NURO
|
1.35 M | - | 5.05 % | $ 9.02 M | USA |
 |
STAAR Surgical Company
STAA
|
57 M | $ 20.21 | 4.55 % | $ 1 B | USA |
 |
Stereotaxis
STXS
|
15.3 M | $ 1.87 | 1.08 % | $ 170 M | USA |
 |
The Cooper Companies
COO
|
1.41 B | $ 70.17 | -1.76 % | $ 14 B | USA |
 |
LeMaitre Vascular
LMAT
|
71.1 M | $ 108.49 | -0.24 % | $ 2.46 B | USA |
 |
Microbot Medical
MBOT
|
1.91 M | $ 2.4 | 1.27 % | $ 110 M |  Israel |
 |
Nephros
NEPH
|
5.83 M | $ 2.87 | -2.21 % | $ 29.8 M | USA |
 |
Envista Holdings Corporation
NVST
|
1.23 B | $ 25.81 | -0.35 % | $ 4.34 B | USA |
 |
Milestone Scientific
MLSS
|
2.57 M | $ 0.28 | -4.86 % | $ 23 M | USA |
 |
Alcon
ALC
|
3.58 B | $ 74.56 | -1.26 % | $ 40.4 B |  Schweiz |
 |
Pro-Dex
PDEX
|
47.1 M | $ 51.67 | 1.33 % | $ 170 M | USA |
 |
Retractable Technologies
RVP
|
38.2 M | $ 0.69 | 2.99 % | $ 20.7 M | USA |